Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $282

Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $276 to $282.